[go: up one dir, main page]

AR038385A1 - Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo - Google Patents

Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo

Info

Publication number
AR038385A1
AR038385A1 ARP030100294A ARP030100294A AR038385A1 AR 038385 A1 AR038385 A1 AR 038385A1 AR P030100294 A ARP030100294 A AR P030100294A AR P030100294 A ARP030100294 A AR P030100294A AR 038385 A1 AR038385 A1 AR 038385A1
Authority
AR
Argentina
Prior art keywords
controlled release
cetpi
inhibitor
dosing
transfer protein
Prior art date
Application number
ARP030100294A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR038385A1 publication Critical patent/AR038385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Formas de dosificación farmacéutica de liberación controlada de un inhibidor de proteína de transferencia de éster de colesterilo (CETPI), a procedimientos de uso y a procedimientos de preparación de las mismas. En particular, una forma de liberación controlada del CETPI éster etílico del ácido [2R, 4S]-4-[(3,5-bistrifluorometilbencil) metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2H-quinolin-1-carboxílico. Reivindicación 1: Una forma de dosificación de liberación controlada caracterizada porque comprende: (a) una forma de solubilidad potenciada de un inhibidor de proteína de transferencia de éster de colesterilo (CETPI); y (b) un medio de liberación controlada para liberar el citado CETPI; en la que después de la administración a un entorno de uso in vivo, la citada forma de liberación controlada proporciona al menos uno de (i) al menos un 50 % de inhibición de la proteína plasmática de transferencia de éster de colesterilo durante al menos 12 horas; (ii) una concentración máxima de fármaco en la sangre que es menor o igual que el 80 % de la concentración máxima de fármaco en la sangre proporcionada por una forma de dosificación de liberación inmediata constituida por la misma cantidad de la forma de solubilidad potenciada del CETPI; (iii) un nivel medio de colesterol HDL después de la dosificación durante 8 semanas que es al menos aproximadamente 1,2 veces el obtenido antes de la dosificación; y (iv) un nivel medio de colesterol LDL después de la dosificación durante 8 semanas que es menor o igual que el 90 % del obtenido antes de la dosificación.
ARP030100294A 2002-02-01 2003-01-31 Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo AR038385A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35371902P 2002-02-01 2002-02-01

Publications (1)

Publication Number Publication Date
AR038385A1 true AR038385A1 (es) 2005-01-12

Family

ID=27663244

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100294A AR038385A1 (es) 2002-02-01 2003-01-31 Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo

Country Status (24)

Country Link
US (1) US20030198674A1 (es)
EP (1) EP1474144B1 (es)
JP (1) JP2005522424A (es)
KR (1) KR20040083493A (es)
CN (1) CN1625397A (es)
AR (1) AR038385A1 (es)
AT (1) ATE403432T1 (es)
BR (1) BR0307332A (es)
CA (1) CA2473991C (es)
DE (1) DE60322665D1 (es)
ES (1) ES2309294T3 (es)
GT (1) GT200300023A (es)
HN (1) HN2003000054A (es)
IL (1) IL162870A0 (es)
MX (1) MXPA04005647A (es)
NO (1) NO20043506L (es)
PA (1) PA8565101A1 (es)
PE (1) PE20030806A1 (es)
PL (1) PL371416A1 (es)
RU (1) RU2004123637A (es)
TW (1) TW200303204A (es)
UY (1) UY27643A1 (es)
WO (1) WO2003063868A1 (es)
ZA (1) ZA200404718B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
CA2508840A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
WO2004085996A2 (en) * 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarkers for longevity and disease and uses thereof
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
AU2004282101A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
JP2007517015A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物
ATE402180T1 (de) 2004-03-26 2008-08-15 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US9265731B2 (en) * 2005-01-28 2016-02-23 Bend Research, Inc. Drying of drug-containing particles
CA2601762A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
WO2007092642A2 (en) * 2006-02-09 2007-08-16 Merck & Co., Inc. Polymer formulations of cetp inhibitors
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8834929B2 (en) * 2006-07-21 2014-09-16 Bend Research, Inc. Drying of drug-containing particles
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
WO2008065506A2 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
CA2682752C (en) * 2007-04-05 2015-07-07 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
US8900629B2 (en) 2007-04-05 2014-12-02 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
HUE024898T2 (en) 2007-04-13 2016-02-29 Kowa Co New pyrimidine compound with dibenzylamine structure and drug containing compound
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
PL2187873T3 (pl) 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
AU2012313971B2 (en) 2011-09-27 2016-09-29 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR101610465B1 (ko) 2014-04-11 2016-04-07 국립암센터 다목적용 의료 영상 표지자 및 이의 제조방법
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CN104474553A (zh) * 2014-11-26 2015-04-01 嘉应学院医学院 一种基于β-谷甾醇的药物缓释剂及其制备方法
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN107098946B (zh) * 2016-02-23 2021-01-29 中国药科大学 Cetp抑制剂的合成与用途
WO2020263560A1 (en) 2019-06-26 2020-12-30 Carrier Corporation Transportation refrigeration unit with adaptive defrost
JP2023541997A (ja) * 2020-09-18 2023-10-04 ブリストル－マイヤーズ スクイブ カンパニー 膨潤性コアを含むｔｙｋ２阻害薬の剤形
WO2024189127A1 (en) * 2023-03-14 2024-09-19 Prolevi Bio Ab Compositions for sustained release of poorly soluble active ingredients

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18446A (en) * 1857-10-20 Improvement in steam-plows
US54038A (en) * 1866-04-17 Improvement in priming metallic cartridges
US91643A (en) * 1869-06-22 Improvement in gang-plows
US28895A (en) * 1860-06-26 Machine for wetting paper
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4247498A (en) 1976-08-30 1981-01-27 Akzona Incorporated Methods for making microporous products
US4564488A (en) 1978-07-31 1986-01-14 Akzo Nv Methods for the preparation of porous fibers and membranes
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4490431A (en) 1982-11-03 1984-12-25 Akzona Incorporated 0.1 Micron rated polypropylene membrane and method for its preparation
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5225192A (en) 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4316537A1 (de) 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
KR100204738B1 (ko) * 1994-11-12 1999-06-15 성재갑 콜레스테릴 에스테르 전달 단백질 저해 펩티드 및 이를 포함하는 동맥경화증 예방 및 치료제
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
PT1115693E (pt) 1998-09-25 2007-08-02 Monsanto Co Arial- e heteroaril - heteroalquilaminas terciárias policíclicas substituídas úteis para inibir a actividade da proteína de transferência de éster de colesterilo.
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1239835B1 (en) 1999-12-23 2013-03-20 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
EE200200361A (et) * 1999-12-23 2003-10-15 Pfizer Products Inc. Hüdrogeeli-juhitav ravimi doseerimise vahend
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
BR0210519A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de adsorvatos de fármaco amorfo
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
MXPA04005647A (es) 2005-03-23
KR20040083493A (ko) 2004-10-02
HN2003000054A (es) 2003-11-24
CA2473991A1 (en) 2003-08-07
IL162870A0 (en) 2005-11-20
DE60322665D1 (de) 2008-09-18
PL371416A1 (en) 2005-06-13
PA8565101A1 (es) 2003-11-12
RU2004123637A (ru) 2005-04-20
TW200303204A (en) 2003-09-01
JP2005522424A (ja) 2005-07-28
WO2003063868A1 (en) 2003-08-07
ES2309294T3 (es) 2008-12-16
UY27643A1 (es) 2003-08-29
CN1625397A (zh) 2005-06-08
US20030198674A1 (en) 2003-10-23
ATE403432T1 (de) 2008-08-15
BR0307332A (pt) 2004-12-07
CA2473991C (en) 2009-09-15
PE20030806A1 (es) 2003-09-19
EP1474144A1 (en) 2004-11-10
NO20043506L (no) 2004-10-19
ZA200404718B (en) 2006-11-29
EP1474144B1 (en) 2008-08-06
GT200300023A (es) 2003-09-17

Similar Documents

Publication Publication Date Title
AR038385A1 (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
EP1781256A4 (en) PHOSPHOLIPIDE-GEL COMPOSITIONS FOR DRUG DISPOSAL AND METHOD FOR THE TREATMENT OF ILLNESSES THEREWITH
MXPA02006679A (es) Composicion farmaceutica.
CL2010000434A1 (es) Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
UY27533A1 (es) Composiciones farmacéuticas que contienen oxibutinina
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
EA200870154A1 (ru) Лекарственное средство для местного применения
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
MX2007000117A (es) Una composicion de combinacion.
NO20073457L (no) Stabile sammensetninger av fenofibrat med fettsyreestere
MX9304503A (es) Compuestos antiinflamatorios.
UY27753A1 (es) Formulación farmacéutica que comprende melatonina.
EA200702102A1 (ru) Пластинки, содержащие стероидные гормоны
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
ES2180446A1 (es) Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
AR046665A1 (es) Formulaciones orales de desoxipeganina y sus usos
RU2009127858A (ru) Фармацевтическая композиция, включающая алискирен и авосентан
EA201000990A1 (ru) Лечение дисменореи путем трансдермального введения нестероидных противовоспалительных лекарственных средств

Legal Events

Date Code Title Description
FB Suspension of granting procedure